Receptor tyrosine kinases (RTKs) are transmembrane proteins that convert extracellular growth factor signals into intracellular kinase activity, initiating proliferative and survival cascades. With ~58 RTKs encoded in the human genome (ErbB, VEGFR, MET, FGFR, RET, ALK, ROS1 families), RTK dysregulation through mutation, amplification, or autocrine ligand loops is among the most common oncogenic events in carcinoma. Critically, RTKs are the most tractable class of oncoproteins for therapeutic targeting — both by small-molecule TKIs that occupy the ATP-binding pocket and by monoclonal antibodies targeting the extracellular domain.
Ligand binding induces RTK dimerisation, which triggers trans-autophosphorylation of intracellular tyrosine residues. These phosphotyrosines serve as docking platforms for SH2-domain-containing adaptor proteins (GRB2, SHC, p85/PI3K), scaffolding the assembly of signalling complexes that activate RAS/MAPK and PI3K/AKT cascades. Signal termination is achieved by c-CBL-mediated RTK ubiquitination and lysosomal degradation, and by PTEN/phosphatase-mediated PIP3 dephosphorylation.
Ligand binding induces RTK dimerisation, which triggers trans-autophosphorylation of intracellular tyrosine residues. These phosphotyrosines serve as docking platforms for SH2-domain-containing adaptor proteins (GRB2, SHC, p85/PI3K), scaffolding the assembly of signalling complexes that activate RAS/MAPK and PI3K/AKT cascades. Signal termination is achieved by c-CBL-mediated RTK ubiquitination and lysosomal degradation, and by PTEN/phosphatase-mediated PIP3 dephosphorylation.
Receptor Tyrosine Kinase Activation
Dimerised RTK kinase domains adopt an asymmetric configuration: one kinase (activator) catalytically phosphorylates tyrosines in the other (receiver). The pattern of phosphotyrosines determines which signalling pathways are preferentially activated.
HER3 (kinase-dead RTK) is the most potent PI3K activator in the ErbB family due to 6 YXXM motifs that directly recruit p85-PI3K. HER2/HER3 heterodimers generate maximal PI3K/AKT signalling without requiring adaptor intermediates — explaining the exceptional pro-survival drive of HER2-amplified tumours.
c-CBL E3 ligase ubiquitinates activated EGFR at Tyr1045, promoting receptor internalisation via clathrin-coated vesicles or macropinocytosis. Endosomal receptors are either degraded (lysosomal) or recycled (Rab11-dependent). Autocrine ligand loops in cancer defeat this mechanism.
Cancer exploits RTKs through: activating kinase domain mutations (EGFR exon 19 del/L858R), gene amplification increasing surface receptor density (HER2, EGFR), autocrine ligand loops (VEGFA in clear cell RCC), ligand-independent constitutive activity (EGFRvIII deletion mutant in GBM), and oncogenic fusion proteins (EML4-ALK, RET fusions).
RTK-activating alterations define molecularly distinct cancer subtypes with dramatically different prognoses and treatment responses. EGFR-mutant NSCLC has 18+ month median PFS on osimertinib (vs ~6 months on chemotherapy). HER2+ breast cancer 5-year survival has risen from ~50% to >90% with HER2-directed therapy. ALK-rearranged NSCLC responds to lorlatinib with >75% response rates.
RTK-directed therapy spans monoclonal antibodies (trastuzumab, cetuximab, pertuzumab), TKIs (osimertinib, lorlatinib, alectinib, cabozantinib), bispecific antibodies (amivantamab), and antibody-drug conjugates (T-DXd, sacituzumab govitecan). Resistance invariably develops through secondary kinase domain mutations (EGFR T790M, C797S), bypass track activation (MET amplification, KRAS mutation), or histological transformation.
What makes HER2 different from other ErbB family receptors?
HER2 is unique in lacking a known activating ligand (it is an 'orphan' receptor) and in being the preferred heterodimerisation partner for EGFR, HER3, and HER4. HER2's kinase domain is constitutively active and always functions as the 'activator' kinase in the asymmetric dimer — making amplification extremely effective at driving signalling without requiring any ligand.
Why do anti-EGFR antibodies (cetuximab) fail in KRAS-mutant colorectal cancer?
Cetuximab blocks EGFR extracellular domain, preventing ligand binding and receptor activation. However, if KRAS is constitutively GTP-locked due to oncogenic mutation, KRAS signals continuously regardless of upstream EGFR status. Anti-EGFR therapy has no effect downstream of the mutation point — explaining mandatory RAS testing before prescribing cetuximab or panitumumab.
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway is the most frequently activated oncogenic signalling axis in human cancer, altered in over 70…
Content is based on peer-reviewed scientific literature including data from NCBI, UniProt, PubMed, and TCGA. Gene links reference curated molecular biology databases. For educational purposes only; does not constitute clinical advice.